The follicle stimulating hormone receptor (FSHR) was chosen as a potential target because of its specificity to OC and overexpression in early-stage ovarian cancer cells and malignancy, where it has been shown to exert mitogenic effects and cell proliferation and associated with cancer stem cell properties [43,44]. The gene discussed is FSHR; the disease is ovarian carcinoma.